Recent groundbreaking research has illuminated the intricate communications between the gut and brain, revealing how these interactions significantly influence human eating behaviors. Two comprehensive studies, published in Clinical Gastroenterology and Hepatology and Gastroenterology, delve into the complex neurobiological and socio-environmental factors that govern eating patterns, providing a fresh perspective on the multifaceted mechanisms underpinning digestive health and nutrition.

The gut-brain axis, a bidirectional communication system connecting the central nervous system with the gastrointestinal tract, has gained substantial attention in recent years. These new studies emphasize that this axis is modulated not only by biological factors but also by external life circumstances, such as stress, socioeconomic status, and access to healthcare. Such factors can profoundly impact eating behavior, metabolism, and ultimately, overall health. The integration of microbiome science with neurogastroenterology in these papers marks a significant advance in understanding how the gut-brain network orchestrates complex physiological and psychological responses related to food intake.

One of the key revelations from the first study is how social determinants of health — encompassing variables like income disparity, educational background, and healthcare availability — intersect with the brain-gut-microbiome axis to modulate obesity risk. Stress induced by adverse life conditions appears to disrupt the delicate microbiome balance, consequently affecting neural pathways involved in mood regulation, cognitive decision-making, and hunger signaling. This disruption can drive cravings for calorie-dense foods, fostering patterns that contribute to excessive weight gain. Unpacking these biological-social interactions offers a sophisticated framework to refine therapeutic approaches for obesity, moving beyond simplistic dietary advice toward more personalized and context-aware interventions.

Delving deeper into mechanistic pathways, the study highlights how chronic psychosocial stress modulates hypothalamic-pituitary-adrenal (HPA) axis activity, thereby influencing gastrointestinal function and microbial composition. Elevated cortisol levels, a hallmark of prolonged stress, have been implicated in altering gut permeability and immune responses, which can trigger low-grade inflammation and dysbiosis. These physiological alterations feedback to the brain via vagal afferents and systemic cytokines, perpetuating maladaptive eating impulses and undermining metabolic homeostasis. Such insights underscore the importance of addressing psychosocial elements alongside microbiotic and neurological considerations in managing obesity and related metabolic disorders.

The second paper explores a less-studied but equally critical facet of gut-brain dynamics: the relationship between disorders of gut-brain interaction (DGBI) and avoidant/restrictive food intake disorder (ARFID) symptoms in adults. This pioneering, population-wide investigation reveals a strikingly high prevalence of ARFID symptomatology among individuals with DGBI, suggesting a pervasive and under-recognized clinical overlap. Symptoms such as sensory-based food avoidance, diminished appetite, and anticipatory fear of negative gastrointestinal consequences were commonly reported, highlighting an intricate biopsychosocial interplay mediating eating disorders.

From a pathophysiological perspective, DGBIs—conditions typified by dysregulated gut motility, visceral hypersensitivity, and altered central processing of gastrointestinal signals—likely predispose individuals to restrictive eating behaviors due to persistent discomfort and anxiety. This nexus between physical gut disturbances and restrictive eating patterns warrants routine screening for ARFID symptoms within gastroenterological clinical settings. By integrating gastrointestinal, nutritional, and mental health care, clinicians can better address the heightened health burdens and compromised quality of life experienced by these patients across all body mass indices.

Importantly, these studies converge on the concept that gut-brain communication transcends simple digestive function and plays a pivotal role in the etiology of both overeating and restrictive eating disorders. The complex dialogue between enteric neurons, central brain structures, and the resident microbial community is sensitive to both intrinsic factors—such as genetics and immune activity—and extrinsic stressors including discrimination, trauma, and prior health status. Together, these determinants sculpt the neural circuits governing hunger, satiety, and food-related behaviors.

These discoveries carry profound implications for clinical practice, advocating for a paradigm shift toward multidisciplinary, patient-centered treatment models. Standard approaches focusing solely on caloric intake or gut symptom management may miss critical drivers of maladaptive eating behaviors rooted in neurobiological and psychosocial factors. Advanced diagnostic tools incorporating neuro-gastroenterological assessments and psychometric screening for eating disorders could enable tailored interventions. Furthermore, therapies targeting microbiome composition through diet, probiotics, or fecal microbiota transplantation may become central elements of comprehensive care.

Beyond individual treatment, public health strategies must recognize the influence of social determinants on gut-brain axis function to mitigate obesity and eating disorder prevalence at the population level. Addressing systemic inequities related to income, education, and healthcare access is essential to reduce chronic stress exposures that weaken gut-brain homeostasis. Community-based programs promoting resilience, mental well-being, and nutritional literacy can foster healthier gut-brain interactions and eating habits across diverse demographics.

In sum, this evolving body of research heralds a new frontier in understanding how gut microbes, neural networks, and life contexts collectively govern human nutrition and health. The recognition that “why” patients eat is as crucial as “what” they eat opens expansive avenues for scientific inquiry and clinical innovation. Future investigations will undoubtedly build on these foundational findings to unravel precise molecular mechanisms and develop targeted interventions to enhance digestive and mental health outcomes worldwide.

Subject of Research: Gut-brain interactions and their role in shaping eating behaviors, with a focus on the influence of social determinants and disorders of gut-brain interaction on obesity and avoidant/restrictive food intake disorder symptoms.

Article Title: New Papers Shed Light on Gut-Brain Interactions in Eating Behaviors

News Publication Date: September 2, 2025

Web References:

• Clinical Gastroenterology and Hepatology
• Gastroenterology

Image Credits: Gastroenterology & Clinical Gastroenterology and Hepatology

Keywords:
Gastroenterology, gut-brain axis, microbiome, obesity, eating behavior, avoidant/restrictive food intake disorder, disorders of gut-brain interaction, social determinants of health, neurogastroenterology, psychosocial stress, metabolic health, personalized nutrition

Dr. Mauney’s clinical investigation positions psychedelic-assisted therapy within the domain of functional bowel disorders, an area historically underserved due to the complex interplay of psychological, neurological, and somatic factors. By administering two doses of psilocybin, integrated with structured therapeutic sessions before and after dosing, her trial seeks to unravel how this classic psychedelic modulates interoception—the brain’s perception of internal bodily sensations—and influences gut-brain communication pathways. Functional magnetic resonance imaging (fMRI) is leveraged to capture dynamic neurobiological changes, offering unprecedented insight into the neural circuits implicated in symptom modulation.

Central to Dr. Mauney’s hypothesis is the concept that IBS and related disorders may ensue from "somatic encoding" of early-life trauma, where adverse experiences imprint themselves on the body’s physiological systems and nervous pathways. This paradigm invites a shift beyond symptomatic treatment toward addressing root psychosomatic causes. Psilocybin, with its known capacity to disrupt entrenched neural patterns and facilitate emotional processing, could recalibrate the maladaptive neurobiological signatures that perpetuate chronic gastrointestinal distress.

The impetus for Dr. Mauney’s work began during the COVID-19 pandemic, when an intellectual curiosity sparked by Michael Pollan’s book, "How to Change Your Mind," catalyzed her engagement with the therapeutic potential of psychedelics. Leveraging her background in bacteriology and clinical pediatric gastroenterology, she integrated a translational research perspective. Notably, her mentorship under leading neuroscientists specializing in psychedelics and neurointestinal health at Massachusetts General Hospital provided critical interdisciplinary expertise that shaped the study’s methodology and theoretical framework.

Dr. Mauney emphasizes that traditional medical disciplines often maintain a "schism between mind and body," particularly evident in gastroenterology where psychological and physiological symptoms are inseparably intertwined yet frequently treated in isolation. Her research aims to bridge this divide by deploying an integrative method combining patient-reported outcomes—such as detailed abdominal pain scores—with qualitative narrative accounts and high-resolution neuroimaging data. This dual approach captures both subjective healing experiences and objective neurological correlates, potentially establishing a new model for evaluating functional somatic syndromes.

While her current trial focuses on adult subjects with severe IBS, Dr. Mauney’s pediatric background roots her broader vision in early intervention and trauma-informed care. She highlights systemic societal challenges, including childhood obesity and health inequities, particularly the insufficient alignment of public policies around nutrition, urban planning, and psychosocial support. Her research thus intersects with pressing public health priorities and raises critical questions about the long-term benefits of childhood trauma prevention on adult functional diseases.

The innovative nature of this investigation also challenges clinical paradigms by proposing that psychedelic therapy can serve as a catalyst—not merely for symptom suppression—but for facilitating profound psychological and physiological recalibration. By potentially "unlocking" somatically encoded trauma, such treatments may enable a restorative process capable of achieving sustained functional recovery. The inclusion of fMRI imaging to delineate psychedelics’ modulatory effects on brain-gut networks bolsters the mechanistic understanding necessary to transition these therapies into standard clinical practice.

Dr. Mauney’s personal philosophy deeply informs her scientific approach; she stresses the importance of cultivating authentic, compassionate relationships with patients. This ethos reflects a commitment to treating individuals as whole persons rather than isolated symptom clusters. Her insistence on persistent, meticulous research echoes the maxim "We are what we repeatedly do," symbolizing an ethos of integrity and patient-centered care that permeates her work.

Looking ahead, the scalability of psychedelic-assisted treatments is a key focus. Dr. Mauney envisions refining protocols to facilitate wider accessibility in clinical settings, thus offering hope to the millions globally with treatment-refractory IBS. As psychedelics gain increasing regulatory acceptance and enter late-stage clinical trials across multiple psychiatric and neurological conditions, her work situates gastroenterology at the cutting edge of this therapeutic renaissance.

This study also prompts broader consideration of whether other medical specialties facing treatment-resistant disorders—such as chronic pain syndromes, autoimmune conditions, or neurodevelopmental disorders—could benefit from similar integrative, trauma-informed psychedelic interventions. Dr. Mauney’s research pioneers a new frontier that transcends disciplinary boundaries, suggesting future multidisciplinary bridges between psychiatry, immunology, neurology, and internal medicine.

Published as part of the Genomic Press “Innovators & Ideas” series, this in-depth interview and report provide an insightful window into the scientists driving transformative change. By weaving rigorous scientific detail with personal reflections, this narrative exemplifies how emerging research can resonate beyond academia and capture public imagination. As the psychedelic field enters a new era, Dr. Mauney’s work epitomizes the potential for groundbreaking scientific advances to restore humanity to medicine and unlock healing where traditional approaches have faltered.

Dr. Erin Mauney’s clinical trial and accompanying research not only herald a paradigm shift in the understanding and treatment of functional gastrointestinal disorders but also illuminate the profound interconnectedness of mind and body. Her pioneering use of psilocybin as a modulator of gut-brain interactions serves as a beacon for future investigations poised to redefine how medicine approaches complex, multifaceted illnesses—offering truly holistic pathways to healing for millions worldwide.

Subject of Research: People

Article Title: Erin Mauney: Psychedelics as modulators of the gut-brain interaction

News Publication Date: 3 June 2025

Web References:
DOI link: http://dx.doi.org/10.61373/pp025k.0020

Image Credits: Erin Mauney

Keywords: psilocybin, psychedelic medicine, irritable bowel syndrome, gut-brain axis, interoception, functional gastrointestinal disorders, trauma, neuroimaging, fMRI, pediatric gastroenterology, psychedelic-assisted therapy, clinical trial